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ABSTRACT
Background There is not yet a comprehensive evidence-
based epidemiological report on type 2 diabetes mellitus 
(T2DM) in Nigeria. We aimed to estimate country-wide and 
zonal prevalence, hospitalisation and mortality rates of 
T2DM in Nigeria.
Methods We searched MEDLINE, EMBASE, Global 
Health, Africa Journals Online (AJOL) and Google Scholar 
for population and hospital-based studies on T2DM in 
Nigeria. We conducted a random-effects meta-analysis on 
extracted crude estimates, and applied a meta-regression 
epidemiological model, using the United Nations 
demographics for Nigeria in 1990 and 2015 to determine 
estimates of diabetes in Nigeria for the two years.
Results 42 studies, with a total population of 91 320, met 
our selection criteria. Most of the studies selected were 
of medium quality (90.5%). The age-adjusted prevalence 
rates of T2DM in Nigeria among persons aged 20–79 years 
increased from 2.0% (95% CI 1.9% to 2.1%) in 1990 to 
5.7% (95% CI 5.5% to 5.8%) in 2015, accounting for over 
874 000 and 4.7 million cases, respectively. The pooled 
prevalence rate of impaired glucose tolerance was 10.0% 
(95% CI 4.5% to 15.6%), while impaired fasting glucose 
was 5.8% (95% CI 3.8% to 7.8%). Hospital admission rate 
for T2DM was 222.6 (95% CI 133.1 to 312.1) per 100 000 
population with hyperglycaemic emergencies, diabetic 
foot and cardiovascular diseases being most common 
complications. The overall mortality rate was 30.2 (95% CI 
14.6 to 45.8) per 100 000 population, with a case fatality 
rate of 22.0% (95% CI 8.0% to 36.0%).
Conclusion Our findings suggest an increasing 
burden of T2DM in Nigeria with many persons currently 
undiagnosed, and few known cases on treatment.
INTRODUCTION
Many studies have reported increasing prev-
alence of type 2 diabetes mellitus (T2DM) 
globally.1–3 According to International 
Diabetes Federation (IDF), there were over 
151 million people with diabetes in 2000,1 
194 million in 2003,2 246 million in 2006,3 
285 million in 20104 5 and 415 million in 2015.6 
The WHO reported that people living with 
diabetes globally increased from 108 million 
in 1980 to 422 million in 2014, with over-
weight and obesity being major risk factors.7 
This increase was also observed in Africa, with 
diabetes cases increasing from 4 million to 
25 million between 1980 and 2014.7 Research 
findings have shown that prevalence rates of 
diabetes in urban Africa are in fact similar 
with, or even higher than, what is obtained 
in some developed countries.8 9 This has been 
linked to rapidly changing demographic 
trends, increased rate of urbanisation, 
unhealthy diets and gradual adoption of 
Western lifestyles in many African settings.10
In Nigeria, the most populous country in 
Africa, the prevalence of T2DM has been high 
and still increasing, with the country widely 
reported as having Africa’s highest burden 
of diabetes.10 11 However, there are no known 
country-wide surveys or any reported attempt 
within Nigeria in recent times to specifi-
cally estimate the burden of diabetes in the 
country. The last national survey of non-com-
municable diseases (NCDs) was conducted 
in 1997 with a prevalence of 2.2% reported 
for diabetes,12 and the 2003 national NCDs 
survey was mainly in the South–West region 
and results were inconclusive.13 In the 2013 
IDF global study, a prevalence of 5% was 
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Strengths and limitations of this study
 ► This study provides a comprehensive report on the 
epidemiology of type 2 diabetes mellitus (T2DM) 
in Nigeria since the last nationwide survey of non-
communicable diseases in 1997.
 ► Estimates provided are based on original population 
and hospital-based studies on type 2 diabetes 
conducted across the six geopolitical zones of 
Nigeria.
 ► The study is limited by lack of data on T2DM in 
northern parts of Nigeria, suggesting the need for 
more research in the region.
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estimated for Nigeria, accounting for 3.9 million cases 
among persons aged 20–79 years.8 The researchers specif-
ically noted that Nigeria was among countries without 
up-to-date data on diabetes; hence, the Nigerian estimate 
was modelled from pooled estimates in Cameroon, due to 
relatively similar geographic, ethnic and socioeconomic 
patterns with Nigeria.8
Due to the relatively limited epidemiological evidence 
on the burden of T2DM in Nigeria,11 14 the few reported 
estimates may have been based on advanced modelling 
and extrapolation of very scarce data, and may not 
necessarily represent the true burden of the disease 
in the country.8 15 The WHO reports that there is still 
need for more research on the burden of diabetes, 
including country-specific response to diabetes treat-
ment and management, and anthropological and 
cultural perspectives of diabetes in Africa.7 16 With 
many research, treatment and management gaps 
remaining unaddressed, a study focusing on estimating 
the burden for appropriate public health and policy 
response has been widely advocated.14 We aimed to 
systematically review the literature on T2DM in Nigeria 
towards providing national and regional estimates of 
the prevalence (including undiagnosed cases, persons 
on treatment and mean fasting plasma glucose (FPG) 
concentration), hospitalisation and mortality from 
T2DM in Nigeria.
METHODS
This study was conducted in accordance with the supple-
mentary MOOSE guidelines of systematic reviews of 
observational studies.17
Search terms and strategy
Further to an initial scoping exercise with a librarian, 
Medical Subject Headings (MeSH), search terms and text 
words that fit into relevant health databases, including 
MEDLINE, EMBASE, Global Health and Africa Journals 
Online (AJOL), were identified (table 1).
The databases’ search was conducted on 10 February 
2017, and limited to studies published between 1 January 
1985 and 31 December 2016, to ensure a relatively consis-
tent diabetes diagnostic criteria not earlier than the 
WHO 1985 guidelines, which reflects to some degree 
the current WHO and American Diabetes Association 
(ADA) case definitions.16 18–20 Unpublished documents 
were sourced from Google Scholar and online sites. The 
abstracts of all studies were reviewed and full texts of 
relevant studies were accessed. The references of initially 
accessed studies were further hand-searched for addi-
tional studies and data sources. The authors of relevant 
papers were contacted for missing information.
Eligibility criteria
Studies were included in the review if they met the 
following criteria: (1) population based conducted 
among adults aged 20 years or more, residing in Nigeria, 
and reporting the prevalence, undiagnosed cases and 
treatment rates of type 2 diabetes and/or prediabetes, 
or enough data to compute these estimates; or (2) 
hospital based and providing information on hospitalisa-
tions, complications, death rates or case fatality rates of 
T2DM in a Nigerian population.
We excluded studies that were (1) primarily on type 1 
diabetes; (2) conducted on paediatric population (0–14 
years), or among populations of Nigerian origin residing 
outside Nigeria; (3) hospital based without any report on 
Table 1 Search terms
# Searches
1 africa/ or africa, western/ or nigeria/
2 exp vital statistics/
3 (incidence* or prevalence* or morbidity or mortality).tw.
4 (disease adj3 burden).tw.
5 exp ‘cost of illness’/
6 case fatality rate.tw
7 hospital admissions.tw
8 Disability adjusted life years.mp.
9 (initial adj2 burden).tw.
10 exp risk factors/
11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 exp glucose metabolism disorders/ or exp diabetes mellitus/ or exp diabetes mellitus/ or exp diabetes mellitus, type 
2/ or exp diabetic ketoacidosis/ or exp prediabetic state/ or exp glycosuria/ or exp hyperglycemia/ or exp glucose 
intolerance/
13 1 and 11 and 12
14 Limit 13 to ‘1985-current’
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hospitalisations, or deaths due to diabetes complications; 
(4) solely based on self-reported diagnosis of T2DM; (5) 
on diabetes, but conducted among persons with co-mor-
bidities; or (6) case series, reviews, commentaries, letters 
or editorials.
Data extraction
Literature search and assessment of eligible studies 
were conducted by two parallel reviewers, with an eligi-
bility guideline to ensure that the selection criteria were 
consistently applied. Data on location, study period, 
study design, study setting (urban or rural), sample size, 
diagnostic criteria and mean age of the population were 
extracted. These were matched with corresponding data 
on mean FPG, prevalence, undiagnosed cases, persons 
on treatment, hospital admission rates, indications for 
admission, deaths and case fatality rates of T2DM (and 
for impaired glucose tolerance (IGT) or impaired fasting 
glucose (IFG) when available). For studies conducted 
on the same study site, population or cohort, the first 
chronologically published study was selected, and all 
additional data from other studies were included in the 
selected paper. Extracted data were sorted by geopolit-
ical zones in Nigeria, and stored in Microsoft Excel file 
format.
Quality assessment
For each full text selected, we further screened for explicit 
description of methodology, case definitions, blood 
glucose measurements and generalisability of reported 
estimates to a larger population within the geopolitical 
zone. For case definitions, we included studies with 
diagnosis of (1) diabetes—defined as chronic meta-
bolic condition characterised by raised blood glucose 
resulting from impairment in secretion of insulin, its 
action or both, based on FPG levels of ≥126 mg/dL 
(7.0 mmoL/L), or 2-hour postprandial glucose (2 hr-pG) 
reading of ≥200 mg/dL (11.1 mmoL/L) after a glucose 
load of 75 g, or random blood glucose (RBG) read-
ings of ≥200 mg/dL (11.1 mmoL/L);16 18–20 (2) impaired 
glucose tolerance—defined as elevated non-diabetic 
levels of blood glucose, based on blood glucose levels 
of ≥140 mg/dL (7.8 mmoL/L) 2 hours after consuming 
75 g of glucose16 18–20; and (3) impaired fasting glucose—
defined as elevated non-diabetic fasting blood glucose, 
based on blood glucose levels of 110–125 mg/dL 
(6.1–6.9 mmoL/L).16 18–20 To allow for fairly consistent 
pooled estimates, we assessed the appropriateness of 
statistical analyses employed in the estimation of T2DM 
prevalence or mortality, and further assessed studies for 
heterogeneities within and outside various population 
groups. For the quality grading, we adapted a previously 
used quality assessment criteria for studies examining 
the prevalence of chronic diseases (see online supple-
mentary file, for details of the grading criteria).21–24 All 
studies graded as high or moderate quality were included, 
while the low-quality studies were excluded from the 
review.
Outcome measures and analysis
A random-effects meta-analysis, using DerSimonian 
and Laird Method,25 was employed on the individual 
study estimates to arrive at crude national and regional 
summary estimates of prevalence, hospital admission 
and mortality of T2DM in Nigeria. Standard errors were 
determined from the reported crude estimates and popu-
lation denominators, assuming a binominal (or Poisson) 
distribution. Heterogeneity between studies was assessed 
using I-squared (I2) statistics,26 and subgroup analysis was 
conducted to identify potential sources of heterogeneity. 
Population-based data (reporting on T2DM prevalence) 
and hospital-based data (reporting on hospitalisations, 
complications and deaths) were analysed separately. Due 
to limited data, a meta-regression epidemiological model 
was only applied to T2DM prevalence rates. The model 
was based on aggregated age from each study (as these 
had more data points), and adjusted for study period and 
sample size. Due to demographic and epidemiological 
transitions, it is understandable that the prevalence rates 
of diabetes and most chronic diseases may increase with 
age;10 however, the relationship may not be linear. Hence, 
in our preliminary analyses, we experimented with various 
models (linear, exponential, polynomial, logarithmic, 
etc) to determine which was most predictive, that is, the 
model with the greatest proportion of variance (R2) of 
diabetes prevalence as explained by age. This was applied 
to the final model, and the best fit was used to determine 
the number of T2DM cases at midpoints of the United 
Nation (UN) population 5-year age groups for Nigeria 
for the years 1990 and 2015. Our data analysis has been 
described in detail in previous studies.27 28 All statistical 
analyses were conducted on STATA (Stata V.13).
Ethical review
This study is a review of publicly available literature and 
data on T2DM in Nigeria. Ethical review was therefore not 
required for this study. The study was however conducted 
in strict compliance to the MOOSE guidelines.
RESULTS
Search results
Our databases’ search returned 1664 studies (MEDLINE 
505, EMBASE 975, Global Health 132 and AJOL 52). 
Additional seven studies were identified through Google 
Scholar and search of reference list of relevant studies. 
There were 1232 studies assessed after duplicates 
were removed. On applying the inclusion and exclu-
sion criteria, 1164 studies were excluded, and of the 
remaining 68 studies, 26 were excluded on applying the 
quality criteria (table 2, see online supplementary file). A 
total of 42 studies29–70 were finally selected for the review 
(figure 1).
Study characteristics
Of the 42 retained studies, 36 were population-based 
cross-sectional studies reporting on prevalence of T2DM 
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and 6 were hospital based reporting on hospitalisations, 
complications and deaths from T2DM (table 2). Most 
studies (15) were conducted in the South–West region 
of Nigeria, followed by the South–East and South–South 
with 8 studies each. The North–West had four studies, 
North-Central three and North–East two. Two studies 
were conducted across multiple regions in the country. 
Study period ranged from 1988 to 2015, with 20 studies 
(47.6%) conducted after 2010. There were 23 studies 
(54.7%) conducted in urban settings. Excluding hospi-
tal-based studies, the total population included in the 
review was 91 320, with a mean age of 48.9 years (table 2). 
Of the 42 included studies, 4 (9.5%) met the criteria for 
high level of quality while 38 (90.5%) met the criteria 
for moderate level of quality. The risk of bias observed 
across studies included selection bias due to sampling 
(33.3%, 14/42) and non-reporting of response rate 
(35.7%, 15/42). Measurement bias was minimal as all 
the included studies used standard diagnostic criteria to 
ascertain the prevalence of diabetes. However, the funnel 
plot was asymmetrical, with this suggestive of publication 
bias across selected studies (figure 2).
Outcome measures
Prevalence rates
The lowest prevalence of T2DM was 0.8% recorded 
in Ibadan, South–West Nigeria in 1995,68 and Sokoto, 
North–West Nigeria in 2013,36 both with mean ages 38.3 
and 40.8 years, respectively. The highest prevalence rates 
of T2DM were reported among oil company workers in 
Port Harcourt in 2001 (26.3%, mean age 61.5 years)50 
and Uyo in 2010 (10.5%, mean age 49.8 years),46 in 
Figure 1 Flow chart of selection of T2DM studies in Nigeria. AJOL, Africa Journals Online; T2DM, type 2 diabetes mellitus.
group.bmj.com on May 26, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
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Figure 2 Funnel plot showing distribution of selected studies. T2DM, type 2 diabetes mellitus.
Figure 3 Pooled prevalence rate of T2DM in Nigeria.T2DM, type 2 diabetes mellitus.
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South–South Nigeria, which is possibly due to the higher 
socioeconomic statuses in these settings (table 2).
From all studies, the pooled crude prevalence of T2DM 
was 4.1% (95% CI 3.3% to 4.9%), with 4.4% (95% CI 
3.3% to 5.9%) among men and 4.1% (95% CI 3.1% to 
5.1%) among women. In the subgroup analysis, the prev-
alence was higher among urban dwellers at 5.3% (95% 
CI 3.5% to 7.0%), compared with 3.5% (95% CI 2.5% to 
4.6%) among rural dwellers (figure 3, table 3).
The South–South region of Nigeria had the highest 
pooled prevalence of T2DM at 8.5% (95% CI 5.1% to 
11.9%), followed by the North–East and South–East 
regions, at 4.6% (95% CI 0.3% to 8.8%) and 3.7% (95% 
CI 3.3% to 4.2%), respectively. The North-Central had the 
lowest pooled prevalence at 2.0% (95% CI 0.7% to 3.3%). 
Over the study period, the highest prevalence of T2DM 
was observed in the period 2000–2009 and 2010–2015 at 
6.9% (95% CI 3.9% to 10.1%) and 4.0% (95% CI 3.3% 
to 4.7%), respectively. The pooled prevalence rates in the 
period 1985–1989 and 1990–1999 were 1.6% (95% CI 
1.2% to 1.9%) and 1.4% (95% CI 0.8% to 2.1%), respec-
tively. In the age group analysis, the highest prevalence 
was observed in the older age intervals of 60–69, 70–79 
and 80+ years at 6.8% (95% CI 4.1% to 9.5%), 6.4% (95% 
CI 1.7% to 11.1%) and 9.9% (95% CI 2.7% to 17.2%), 
respectively (table 4).
Undiagnosed cases of T2DM, expressed as a percentage 
of all T2DM cases in each study, ranged from 7.8% in 
Uyo (South–South)46 to 75% in Dakace village in Zaria 
(North–West),34 with a pooled rate of 39.4% (95% 
CI 26.0% to 52.7%). T2DM cases on treatment, also 
expressed as a percentage of all T2DM cases in each study, 
ranged from 19.6% in Ido-Ekiti (South–West)67 to 50% in 
Sokoto (North–West),37 with a pooled rate of 32.7% (95% 
CI 23.5% to 41.8%) (table 3).
From all studies, prevalence of IGT ranged from 2.2% 
in Ibadan (South–West)68 to 19.6% in Calabar (South–
South),48 and IFG from 1.1% in Umudike (South–East)39 
to 16.9% in Sokoto (North–West).35 The pooled preva-
lence of IGT was 10.0% (95% CI 4.5% to 15.6%), with 
10.3% (95% CI 0.7% to 19.9%) among men and 11.9% 
(95% CI 2.5% to 21.2%) among women. The pooled 
prevalence of IFG was 5.8% (95% CI 3.8% to 7.8%), with 
4.9% (95% CI 2.6% to 7.2%) among men and 4.8% (95% 
CI 3.0% to 6.6%) among women (figures 4 and 5, and 
table 3).
The mean FPG concentration was not too different 
across studies ranging from 4.0 mmoL/L in Port Harcourt 
(South–South)47 to 5.9 mmoL/L in Gindiri-Plateau 
(North-Central),31 with a pooled rate of 5.1 mmoL/L 
(95% CI 4.9 to 5.4) (figure 6). The pooled mean FPG 
rates among men and women were also almost the same 
at 4.6 mmoL/L (95% CI 4.0 to 5.2) and 4.7 (95% CI 4.0 to 
5.3), respectively (table 3).
Hospitalisation, mortality and case fatality rates
Hospital data on T2DM were based on catchment popula-
tion of the hospital. Crude hospital admission rate ranged 
from 23.9 to 763.8 per 100 000 population, with a pooled 
rate of 222.6 (95% CI 133.1 to 312.1) per 100 000 popu-
lation. Hyperglycaemic emergencies (mainly diabetic 
ketoacidosis and hyperosmolar non-ketotic coma), 
diabetic foot, uncontrolled hypertension and stroke 
were the most common complications or indications of 
admission, with pooled rates at 36.1% (95% CI 13.9% to 
58.4%), 19.6% (95% CI 12.3% to 26.9%), 16.7% (95% 
CI 13.4% to 20.1%) and 8.7% (95% CI 7.4% to 10.0%), 
respectively (table 5).
The crude mortality rate for T2DM ranged from 0.97 
to 105.3 per 100 000 population. The overall mortality 
Table 3 Pooled prevalence rates of T2DM, IGT, IFG and mean FPG in Nigeria
Extracted data
All Men Women
Pooled estimate 
(95 % CI) I2, p value
Pooled estimate 
(95 % CI) I2, p value
Pooled estimate 
(95 % CI) I2, p value
T2DM (%) 4.1 (3.3 to 4.9) 96.4%, 
p=0.000
4.4 (3.3 to 5.9) 92.9%, p=0.000 4.1 (3.1 to 5.1) 90.4%, p=0.000
Undiagnosed 
T2DM (%)*
39.4 (26.0 to 52.7) 92.5%, 
p=0.000
– – – –
T2DM on 
treatment (%)*
32.7 (23.5 to 41.8) 44.2%, 
p=0.111
– – – –
IGT (%) 10.0 (4.5 to 15.6) 98.0%, 
p=0.000
10.3 (0.7 to 19.9) 97.8%, p=0.000 11.9 (2.5 to 21.2) 97.4%, p=0.000
IFG (%) 5.8 (3.8 to 7.8) 93.4%, 
p=0.000
4.9 (2.6 to 7.2) 89.7%, p=0.000 4.8 (3.0 to 6.6) 85.1%, p=0.000
Mean FPG 
(mmol/L)
5.1 (4.9 to 5.4) 5.0%, p=0.395 4.6 (4.0 to 5.2) 10.0%, p=0.999 4.7 (4.0 to 5.3) 10.0%, p=1.000
*Represents percentage of overall T2DM cases; there were no data to pool estimates separately for men and women.
I2 represents the variation in pooled estimate attributable to heterogeneity.
p Value represents level of significance.
FPG, fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus.
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Table 4 Overview of subgroup meta-analysis of type 2 diabetes mellitus (T2DM) in Nigeria
Subgroup T2DM prevalence % (95% CI) I2, p value
Setting Urban 5.3 (3.5 to 7.0) 96.6%, p=0.000
Rural 3.5 (2.5 to 4.6) 84.0%, p=0.000
Mixed* 3.1 (1.6 to 4.5) 98.1%, p=0.000
Geopolitical zone North-Central 2.0 (0.7 to 3.3) 62.4%, p=0.070
North–East 4.6 (0.3 to 8.8) 83.5%, p=0.014
North–West 3.0 (0.8 to 5.2) 84.4%, p=0.000
South–East 3.7 (3.3 to 4.2) 0.0%, p=0.414
South–South 8.5 (5.1 to 11.9) 96.8%, p=0.000
South–West 3.2 (1.9 to 4.5) 96.8%, p=0.000
Year 1985–1989 1.6 (1.2 to 1.9) 0.0%, p=0.354
1990–1999 1.4 (0.8 to 2.1) 54.3%, p=0.068
2000–2009 6.9 (3.9 to 10.1) 97.3%, p=0.000
2010–2015 4.0 (3.3 to 4.7) 90.1%, p=0.000
Age (years) 20–29 1.1 (0.3 to 1.9) 80.3%, p=0.000
30–39 4.7 (2.9 to 6.6) 91.9%, p=0.000
40–49 4.1 (3.1 to 5.1) 96.5%, p=0.000
50–59 5.1 (3.5 to 6.7) 92.4%, p=0.000
60–69 6.8 (4.1 to 9.5) 95.0%, p=0.000
70–79 6.4 (1.7 to 11.1) 74.2%, p=0.021
80+ 9.9 (2.7 to 17.2) 16.1, p=0.275
*Study conducted in rural and urban settings with an overall estimate reported.
I2 represents the variation in pooled estimate attributable to heterogeneity.
p Value represents level of significance.
Figure 4 Pooled prevalence rate of IGT in Nigeria. IGT, impaired glucose tolerance.
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rate from all studies was 30.2 (95% CI 14.6 to 45.8) per 
100 000 population, with a case fatality rate of 22.0% 
(95% CI 8.0% to 36.0%) (table 5). Assuming sociodemo-
graphic and epidemiological changes in Nigeria were fully 
considered, this would amount to 54 297 (26 249–82 344) 
deaths in Nigeria in 2015 based on the UN population 
projections for Nigeria.
Figure 5 Pooled prevalence rate of IFG in Nigeria. IFG, impaired fasting glucose.
Figure 6 Pooled mean FPG concentration in Nigeria. FPG, fasting plasma glucose.
group.bmj.com on May 26, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
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Meta-regression model
The meta-regression modelling, adjusted for study period 
and sample size, was applied to mean ages and crude 
prevalence rates from all studies, as these generated more 
data point. The modelling revealed an increasing preva-
lence with age (p<0.05) (table 6, figure 7).
Using the UN demographic projections for Nigeria, the 
age-adjusted prevalence rates of T2DM in Nigeria were 
2.0% (95% CI 1.9% to 2.1%) and 5.7% (95% CI 5.5% 
to 5.8%) in 1990 and 2015, accounting for over 874 000 
and 4.7 million T2DM cases, respectively, among persons 
aged 20–79 years. This represents over 440% increase 
in overall T2DM cases among persons aged 20–79 years 
between the two years (table 7).
DISCUSSION
With over 50% of studies conducted after 2010, our report 
suggests that research outputs on T2DM in Nigeria may 
be gradually increasing, although these may not be evenly 
distributed across the country as most studies (79%) 
originated form the Southern parts of the country. The 
evidence pool of diabetes, as reported by many experts, 
still remain limited across Nigeria and many parts of 
Africa.16
Our 1990 estimate is in keeping with the 1997 
nationwide diabetes prevalence (2.2%) reported by 
Akinkugbe.12 Although Abubakari and Bhopal reported 
a relatively higher diabetes prevalence (6.8%) in 2000,71 
this may be expected as the seven studies included in their 
report were conducted among persons aged 40 years or 
older, and mainly in Southern parts of Nigeria, where we 
also reported higher prevalence rates in contrast to the 
Northern regions. However, our 2015 prevalence may 
further indicate an increasing trend in the prevalence 
of diabetes in Nigeria with over 440% increase in T2DM 
cases over the 1990 estimate. This is an important finding 
in this study, which is in congruence with the estimates 
reported by Guariguata and colleagues in the IDF global 
study, with a diabetes prevalence rates of 5% reported for 
Nigeria in 2013.8 The increasing rate of T2DM has also 
been documented across several African settings.1 3–5 7 72 
Mbanya and colleagues specifically noted that diabetes 
prevalence is increasing in sub-Saharan Africa, with a 
regional prevalence of 2%–3% in mid-1990s increasing 
to about 4.6% in 2010.10 However, the 2015 Nigerian 
T2DM prevalence reported in this study is higher than 
the prevalence of adult diabetes reported in Cote d’Ivoire 
(2.3%), Ghana (1.9%) and Senegal (1.8%), according to 
Table 5 Hospitalisation, mortality and case fatality rate of  type 2 diabetes mellitus (T2DM) in Nigeria
Data Pooled estimate (95% CI) I2, p value
Hospital admission rate* (per 100 000) 222.6 (133.1 to 312.1) 99.8%, p=0.000
Indication for hospital 
admissions† (%)
Hyperglycaemic emergencies 36.1 (13.9 to 58.4) 99.4%, p=0.000
Diabetic foot 19.6 (12.3 to 26.9) 95.7%, p=0.000
Uncontrolled hypertension 16.7 (13.4 to 20.1) 43.6%, p=0.170
Stroke 8.7 (7.4 to 10.0) 0.0%, p=0.574
Neuropathy 7.7 (2.3 to 13.2) 95.1%, p=0.000
Sepsis 7.7 (5.3 to 10.1) 0.0%, p=0.732
Hypoglycaemia 5.1 (0.9 to 9.3) 94.8%, p=0.000
Nephropathy 4.2 (3.2 to 5.3) 27.0%, p=0.250
Mortality rate* (per 100 000) 30.2 (14.6 to 45.8) 99.2%, p=0.000
Case fatality rate‡ (%) 22.0 (8.0 to 36) 99.5%, p=0.000
*Estimate based on reference population of the hospital catchment area.
†Percentage of all T2DM hospital admissions.
‡Represents proportion of deaths from T2DM hospital admissions.
Table 6 Results of the meta-regression modelling
Prevalence Coef. Std. Err. t P>t Upper 95% CI Lower 95% CI
Age 0.0898737 0.0411097 2.19 0.032 0.0078621 0.1718853
Year 0.1253705 0.0630606 1.99 0.051 −0.000432 0.251173
_cons −251.0127 126.3341 −1.99 0.051 −503.0424 1.017032
Note:REML estimate of between-study variance (tau2)=16.33.
% residual variation due to heterogeneity (I-squared_res)=92.55%.
Proportion of between-study variance explained (Adj R-squared)=11.44%.
Joint test for all covariates in Model (F)=4.90.
With Knapp-Hartung modification Prob > F=0.0102.
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the 2015 IDF atlas,6 suggesting a relatively higher burden 
in Nigeria compared with other West African countries.
Meanwhile, the mean country-wide FPG estimated 
in this study, to the best of our knowledge, is the first 
reported in Nigeria. At a mean FPG concentration of 
5.1 mmoL/L, many people across Nigeria may appar-
ently be approaching the prediabetic states. This 
therefore may be suggestive of the high IGT and IFG 
prevalence rates reported in this study. The implication, 
based on experts’ reports, is that regions with relatively 
low diabetes prevalence but with fairly high prevalence 
of IGT and IFG may be at an early phase of a diabetes 
epidemic.73 The sex distribution of our estimate is also 
consistent with many reports, with IGT affecting more 
women than men, and IFG vice versa.16 There is still 
no sufficient explanation for this sex difference, but 
increasing prevalence of diabetes observed among 
African women may be due to the relatively higher 
Figure 7 Meta-regression epidemiological modelling showing relationship between prevalence of T2DM and mean age of the 
population.T2DM, type 2 diabetes mellitus.Note: T2DM prevalence (y), age (x), year (z) and size of the bubble correspond to 
study sample size. Coefficients of ‘x’ and ‘z’ are ‘0.0899’ and ‘0.125’ for the meta-regressed line, with an intercept of ‘−251’.
Table 7 Age-adjusted prevalence rates and cases of type 2 diabetes mellitus (T2DM) in Nigeria in 1990 and 2015
Age group
1990 2015
Nigeria 
population (000s) Prevalence* (%)
T2DM cases 
(000s)
Nigeria 
population (000s) Prevalence* (%)
T2DM cases 
(000s)
20–24 8160.431 0.52 42.744 15 981.820 3.66 584.743
25–29 6920.907 0.97 67.361 14 051.040 4.11 577.259
30–34 5833.290 1.42 82.996 12 102.270 4.56 551.597
35–39 4876.116 1.87 91.295 9982.646 5.01 499.861
40–44 4140.621 2.32 96.137 7767.685 5.46 423.867
45–49 3579.784 2.77 99.207 6008.701 5.91 458.783
50–54 2949.801 3.22 95.007 4993.836 6.36 381.901
55–59 2373.829 3.67 87.127 4146.148 6.81 339.846
60–64 1861.811 4.12 76.703 3325.733 7.25 300.795
65–69 1373.048 4.57 62.739 2554.200 7.70 256.224
70–74 905.270 5.02 45.434 1821.521 8.15 208.264
75–79 499.574 5.47 27.318 1077.611 8.60 156.711
Total 
(age adjusted) 
20–79 years
43 474.480 2.01 874.068 83 813.210 5.66 4739.851
Lower CI – 1.88 817.321 – 5.50 4609.726
Upper CI – 2.14 930.354 – 5.81 4869.547
*Estimate based on meta-regression epidemiological modelling adjusted for year and sample size from each study.
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prevalence of overweight and obesity among women 
across many African settings,71 74 who have wrongly 
associated this with healthy living, and possibly been 
contented with the better social status it offered them.
Rapid urbanisation, as an important driver of the 
increasing burden of T2DM in Africa,10 was also confirmed 
in our report, with prevalence among urban dwellers well 
above the rural dwellers. Africa, and Nigeria in particular, 
is experiencing fastest rate of urbanisation globally, with 
over a third of the population currently residing in urban 
areas, and this is expected to increase to about 45% by 
2025.75 76 This may also explain the higher T2DM preva-
lence in Southern Nigeria, a relatively urbanised region 
compared with the Northern parts, which is in fact further 
characterised by nomadic lifestyles. Age was another 
factor noted in our report, with higher prevalence rates 
observed in the older age groups. Experts have revealed 
a rising prevalence of diabetes with increasing age, partic-
ularly due to continued exposure to several other risks 
occasioned by prolonged life.10 77
Our estimated mortality rate from T2DM in Nigeria 
is relatively lower compared with the overall rate (111.1 
per 100 000 population) reported for the African region 
in the WHO global report.7 This may be due to the few 
data points on diabetes deaths in our study, and the 
fact that individual mortality rates were based on ‘large’ 
reference population of the hospital where the study was 
conducted. In the 2016 WHO diabetes profile, about 
28 000 diabetes deaths were estimated in Nigeria, stating 
however that the estimates have high degree of uncer-
tainty as there were no available national mortality data 
to compute these estimates.15 However, our estimates 
show hospital admissions (from complications) and case 
fatality rates were comparatively higher in Nigeria, with 
hyperglycaemic emergencies, diabetic foot and cardio-
vascular diseases being the most common indications. 
In Nigeria, there have been reports that many diabetes 
cases present to health facilities at advanced stages of 
the disease.14 Acute complications of diabetes, mainly 
diabetic ketoacidosis, hyperosmolar non-ketotic coma 
and hypoglycaemia, are frequent indications of hospital 
emergencies in Nigeria, with high mortalities recorded.56 
High numbers of undiagnosed cases and low treatment 
rates, as estimated in our study, may also be major factors 
responsible for the prevalent complications and high 
mortality rates. Recent reports within Nigeria show that 
undiagnosed cases of diabetes accounted for about 40% 
of the diabetes burden in the country.11 According to IDF, 
about two million undiagnosed diabetes cases were esti-
mated in Nigeria in 2013, with this responsible for over 
40 000 deaths resulting from diabetes and its complica-
tions in the country.8 Personal health cost from diabetes, 
mostly out of pocket, may have also affected hospital visits 
and use of medications. The lack of a fully functional 
and equitable national health insurance scheme14 means 
many people with diabetes would prefer to stay at home, 
visit substandard facilities or patronise traditional herbal 
healers, due to high cost of treatment and medications, 
only to present at an advanced stage of the disease to 
standard health facilities with widespread complications. 
Kirigia and colleagues estimated that the 7.1 million cases 
of diabetes reported in Africa in 2000 accounted for a 
regional economic loss of about 25.5 billion US$, equiv-
alent to about $3633 per diabetic case.78 The need for 
insulin and other medications was responsible for the 
bulk of the direct cost, accounting for about $8.1 billion 
($1154/diabetic case).78 79
While we attempted to provide population repre-
sentative estimates of the burden of T2DM in Nigeria, 
we however could have been limited by a number of 
factors. First, retained studies were not evenly spread 
across various parts of Nigeria. Most studies selected were 
conducted in the Southern geopolitical zones of Nigeria, 
with the Northern zones having nine studies (21.4%). 
Data from many studies were also incomplete, as results 
of some studies, with explicit sampling strategy and study 
designs, were not always detailed. Besides, data points on 
age and sex-specific prevalence, including corresponding 
prevalence for urban and rural settings, were not always 
provided across studies. There were also sources of hetero-
geneity from study designs, measurement protocols and 
individual and population differences across selected 
studies. However, our selection and quality criteria may 
have excluded low-quality studies, and we conducted 
subgroup meta-analyses on selected studies to identify 
other sources of heterogeneity that may further aid the 
interpretation of results. There were few data points from 
hospital-based studies and representative population 
denominators were not provided. As hospital admissions 
and mortality rates were based on relatively larger catch-
ment population of the hospital, an underestimation may 
not be ruled out. Finally, although we controlled for study 
period and sample population in our modelling, we are 
aware there could be uncertainties in our reported esti-
mates of T2DM in Nigeria for 1990 and 2015, as varying 
population contexts, blood glucose measurements, case 
definitions and social determinants of health, beyond 
mean age of the population, are important factors that 
could have affected real-time trends. However, with 42 
studies selected across all six geopolitical zones of Nigeria, 
and a total population of 91 320 included, our estimates 
may still point to a near-precise burden of T2DM in 
Nigeria.
Conclusion
Our findings suggest an increasing burden of T2DM in 
Nigeria with many persons currently undiagnosed, and 
few known cases on treatment. The rising burden of 
diabetes has presented huge cost to individuals, society 
and the Nigerian government. There is still need for 
more research on T2DM, including specific response 
to diabetes treatment and management, particularly 
in Northern Nigeria, where few researches have been 
conducted to date. We hope our findings may help 
towards improved research, control, treatment and 
policy response to diabetes in Nigeria.
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